尼索地平

C₂₀H₂₄N₂O₆

388.41

264-407-7

MFCD00478055

329818405

NA.77

Nisoldipine has been used:

• as a hit-antagonist to study its effects on oxytocin (OT)-induced myometrial Ca²⁺-mobilization and its potency to dampen uterine myometrial contractions
• as a calcium channel blocker to study its effects on cell viability in a human hepatic cancer HepG2 and rat renal epithelial NRK52E cell line
• as a component of the external IK1 recording solution to study the action potential in human pluripotent stem cell−derived cardiomyocytes (hiPS-CMs)

L-type (CaV1.2) calcium channel blocker; dihydropyridine-type calcium channel blocker with selectivity for smooth muscle (CaV1.2b) over cardiac muscle (CaV1.2a). Arterial vasodilator and antihypertensive agent.

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. N0165.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

100

≥98% (HPLC)

powder

yellow

DMSO: >10 mg/mL

Bayer

room temp

COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OCC(C)C

1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3

VKQFCGNPDRICFG-UHFFFAOYSA-N

human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)

10, 50 mg in glass bottle

GHS07

Warning

H302

P264 - P270 - P301 + P312 - P501

Acute Tox. 4 Oral

11 - Combustible Solids

WGK 1